CA1003820A - Steroid compounds - Google Patents

Steroid compounds

Info

Publication number
CA1003820A
CA1003820A CA132,814A CA132814A CA1003820A CA 1003820 A CA1003820 A CA 1003820A CA 132814 A CA132814 A CA 132814A CA 1003820 A CA1003820 A CA 1003820A
Authority
CA
Canada
Prior art keywords
steroid compounds
steroid
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA132,814A
Other languages
English (en)
Other versions
CA132814S (en
Inventor
Gordon H. Phillipps
Peter J. May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Laboratories Ltd
Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd
Application granted granted Critical
Publication of CA1003820A publication Critical patent/CA1003820A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
CA132,814A 1971-01-20 1972-01-20 Steroid compounds Expired CA1003820A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB278771A GB1384372A (en) 1971-01-20 1971-01-20 Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids

Publications (1)

Publication Number Publication Date
CA1003820A true CA1003820A (en) 1977-01-18

Family

ID=9745890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA132,814A Expired CA1003820A (en) 1971-01-20 1972-01-20 Steroid compounds

Country Status (17)

Country Link
JP (1) JPS5611720B1 (nl)
AU (1) AU473868B2 (nl)
BE (1) BE778285A (nl)
CA (1) CA1003820A (nl)
CH (1) CH602786A5 (nl)
DE (1) DE2202691A1 (nl)
DK (1) DK132894C (nl)
ES (1) ES399057A1 (nl)
FR (1) FR2122539B1 (nl)
GB (1) GB1384372A (nl)
HK (1) HK34278A (nl)
IE (1) IE36000B1 (nl)
IL (1) IL38589A (nl)
NL (1) NL172511C (nl)
NO (1) NO137321C (nl)
SE (1) SE383522B (nl)
ZA (1) ZA72401B (nl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2365102C2 (de) * 1973-12-21 1982-12-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue Pregnansäure-Derivate
DE2444618C2 (de) * 1974-09-16 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue Pregnan-21-säure-Derivate
DE2319479C2 (de) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
SE427276B (sv) * 1975-04-03 1983-03-21 Hoffmann La Roche Forfarande for framstellning av d-homosteroider
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
IT1114534B (it) * 1978-02-08 1986-01-27 Glaxo Group Ltd Steroide anti-infiammatorio della serie dell'androstano composizioni che lo contengono e procedimento per produrlo
CA1138857A (en) * 1979-01-24 1983-01-04 Leo Alig D-homosteroids
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
BRPI0113042B8 (pt) 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
BR0209271A (pt) 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7419971B2 (en) 2003-06-19 2008-09-02 Bodor Nicholas S Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application
JP4893305B2 (ja) 2003-06-19 2012-03-07 ボーダー、ニコラス・エス 局所又は他の局部投与用のソフト抗炎症性ステロイドの活性及び/又は作用持続性の増強
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
US7579335B2 (en) 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
DE102010029875A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
DE102010029877A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids

Also Published As

Publication number Publication date
ZA72401B (en) 1973-09-26
AU3811072A (en) 1973-07-26
BE778285A (fr) 1972-07-20
CH602786A5 (nl) 1978-08-15
IE36000L (en) 1972-07-20
IL38589A (en) 1976-06-30
SE383522B (sv) 1976-03-15
IL38589A0 (en) 1972-03-28
DE2202691A1 (de) 1972-08-03
NL172511B (nl) 1983-04-18
NL7200818A (nl) 1972-07-24
HK34278A (en) 1978-07-07
JPS5611720B1 (nl) 1981-03-16
NO137321B (no) 1977-10-31
DK132894B (da) 1976-02-23
DK132894C (da) 1976-07-26
NO137321C (no) 1978-02-08
AU473868B2 (en) 1976-07-08
FR2122539B1 (nl) 1975-11-28
FR2122539A1 (nl) 1972-09-01
IE36000B1 (en) 1976-07-21
ES399057A1 (es) 1974-11-01
GB1384372A (en) 1975-02-19
NL172511C (nl) 1983-09-16

Similar Documents

Publication Publication Date Title
AU473868B2 (en) Steroid compounds
CA1017336A (en) Divinyl-diphenyl compounds
AU459132B2 (en) Etrachlorophthalide compounds
AU466025B2 (en) Aminohalopyridyloxy compounds
CA1026346A (en) Triazolyphosphorus compounds
CA1006163A (en) Arylaminopyridine compounds
CA981269A (en) 3-carbamoyl-4-phenyl-quinoline compounds
AU466453B2 (en) Triaszolothienodiazepine compounds
CA977345A (en) Perfluoroalkyl-phosphorus compounds
AU464251B2 (en) Steroid compounds
CA955929A (en) Steroids
CA1019871A (en) Arc- and track - resistant polyepoxide - polysiloxane compounds
CA983946A (en) Disilyl-containing compounds
CA1001641A (en) Polyhalobenzylic disulfooxonium compounds
CA989389A (en) Steroids
CA869995A (en) Steroidal compounds
CA879680A (en) Cyclopropyl-substituted steroids
CA869996A (en) Steroids
CA873333A (en) Steroid derivatives
CA880332A (en) Steroid analogs
CA882696A (en) Styryl-pyrazoline compounds
CA889310A (en) Triazinylaminostilbene compounds
CA866216A (en) Gem-difluoramino compounds
CA878508A (en) N-propargyl-pyridinium compounds
CA879704A (en) Triazinylaminocoumarin compounds